Agenus Inc. AGEN

LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Agenus now carries an updated implied fair value of about US$26.33 per share, up from US$19.50, which reflects a change of roughly 35% in the price target used in this analysis. Recent Street commentary links these higher targets to the botensilimab plus balstilimab program in microsatellite stable colorectal cancer and to fresh capital that affects how investors think about financing risk. Read on to see how this evolving narrative around Agenus could matter for your own view of the...

LEXINGTON, Mass., September 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

LEXINGTON, Mass., August 31, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September.

LEXINGTON, Mass., August 28, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.

LEXINGTON, Mass., August 26, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled "Neoadjuvant botensilimab/balstilimab for localized mismatch re

Recently published Checkpoint Inhibitor Refractory Cancer Market Insights report includes a comprehensive understanding of current treatment practices, checkpoint inhibitor refractory cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

The latest analyst update on Agenus centers on a reset of its fair value estimate, with the price target moving from US$30.00 to US$19.50. This change reflects recent Street research that balances optimism about the refocused botensilimab and balstilimab pipeline with caution around financing plans and execution risks. As you read on, you will see how these shifting targets fit into the broader Agenus story and what to watch to keep up with the evolving narrative. Stay updated as the Fair...

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass., August 06, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer.

LEXINGTON, Mass., July 28, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026.

Agenus (AGEN) is back in focus after reporting three year Phase 1b data for its BOT+BAL immunotherapy in refractory microsatellite stable metastatic colorectal cancer, alongside an oversubscribed private placement tied to its registrational ROBBIN trial. See our latest analysis for Agenus. The BOT+BAL data and oversubscribed financing come after a sharp shift in sentiment toward Agenus, with a 7 day share price return of 54.32% and a 30 day share price return of 67.79%, even as the 1 year...

LEXINGTON, Mass., July 17, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, refle

Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of BOT+BAL before colon-cancer surgery, its central development priority. The shift is backed by ...